Updated View On Jazz Pharmaceuticals' 2025 Goals

Ackun/iStock via Getty Images Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) have traded flat to somewhat lower since my November 2022 article and this was largely in line with what the average biotech stock was doing until early November of last year, the time when biotech stocks began to recover and Jazz's share price made no progress. YCharts My view at the time was that the stock was worth approximately $190 per share and more if the company could execute well against its 2025 and long-term goals of reach ...